BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 28983805)

  • 1. Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma.
    Yan X; Clemens PL; Puchalski T; Lonial S; Lokhorst H; Voorhees PM; Usmani S; Richardson PG; Plesner T; Liu K; Orlowski RZ; Losic N; Jansson R; Ahmadi T; Lantz K; Ruixo JJP; Zhou H; Xu XS
    Clin Pharmacokinet; 2018 Apr; 57(4):529-538. PubMed ID: 28983805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials.
    Usmani SZ; Nahi H; Plesner T; Weiss BM; Bahlis NJ; Belch A; Voorhees PM; Laubach JP; van de Donk NWCJ; Ahmadi T; Uhlar CM; Wang J; Feng H; Qi M; Richardson PG; Lonial S
    Lancet Haematol; 2020 Jun; 7(6):e447-e455. PubMed ID: 32470437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
    Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
    Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
    Fau JB; El-Cheikh R; Brillac C; Koiwai K; Mace N; Campana F; Semiond D; Nguyen L
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):649-658. PubMed ID: 33021075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial.
    Mateos MV; Nahi H; Legiec W; Grosicki S; Vorobyev V; Spicka I; Hungria V; Korenkova S; Bahlis N; Flogegard M; Bladé J; Moreau P; Kaiser M; Iida S; Laubach J; Magen H; Cavo M; Hulin C; White D; De Stefano V; Clemens PL; Masterson T; Lantz K; O'Rourke L; Heuck C; Qin X; Parasrampuria DA; Yuan Z; Xu S; Qi M; Usmani SZ
    Lancet Haematol; 2020 May; 7(5):e370-e380. PubMed ID: 32213342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.
    Chari A; Lonial S; Mark TM; Krishnan AY; Stockerl-Goldstein KE; Usmani SZ; Londhe A; Etheredge D; Fleming S; Liu B; Ukropec J; Lin TS; Jagannath S; Nooka AK
    Cancer; 2018 Nov; 124(22):4342-4349. PubMed ID: 30395359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Implications of Complex Pharmacokinetics for Daratumumab Dose Regimen in Patients With Relapsed/Refractory Multiple Myeloma.
    Xu XS; Yan X; Puchalski T; Lonial S; Lokhorst HM; Voorhees PM; Plesner T; Liu K; Khan I; Jansson R; Ahmadi T; Ruixo JP; Zhou H; Clemens PL
    Clin Pharmacol Ther; 2017 Jun; 101(6):721-724. PubMed ID: 27859027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous daratumumab in Asian patients with heavily pretreated multiple myeloma: subgroup analyses of the noninferiority, phase 3 COLUMBA study.
    Iida S; Ishikawa T; Min CK; Kim K; Yeh SP; Usmani SZ; Mateos MV; Nahi H; Heuck C; Qin X; Parasrampuria DA; Gries KS; Qi M; Bahlis N; Ito S
    Ann Hematol; 2021 Apr; 100(4):1065-1077. PubMed ID: 33599794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daratumumab in multiple myeloma: experience of the multiple myeloma GIMEMA Lazio group.
    Vozella F; Siniscalchi A; Rizzo M; Za T; Antolino G; Coppetelli U; Piciocchi A; Andriani A; Annibali O; De Rosa L; Cimino G; La Verde G; De Stefano V; Cantonetti M; di Toritto TC; Petrucci MT
    Ann Hematol; 2021 Apr; 100(4):1059-1063. PubMed ID: 33528611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta-analysis.
    Cao C; Zhou X; Ma Q
    Pharmacol Res Perspect; 2021 Aug; 9(4):e00797. PubMed ID: 34128350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
    Kim K; Phelps MA
    Clin Pharmacokinet; 2023 Jun; 62(6):789-806. PubMed ID: 37129750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study.
    Usmani SZ; Quach H; Mateos MV; Landgren O; Leleu X; Siegel D; Weisel K; Gavriatopoulou M; Oriol A; Rabin N; Nooka A; Qi M; Beksac M; Jakubowiak A; Ding B; Zahlten-Kumeli A; Yusuf A; Dimopoulos M
    Lancet Oncol; 2022 Jan; 23(1):65-76. PubMed ID: 34871550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Daratumumab in multiple myeloma.
    Nooka AK; Kaufman JL; Hofmeister CC; Joseph NS; Heffner TL; Gupta VA; Sullivan HC; Neish AS; Dhodapkar MV; Lonial S
    Cancer; 2019 Jul; 125(14):2364-2382. PubMed ID: 30951198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial.
    Lonial S; Weiss BM; Usmani SZ; Singhal S; Chari A; Bahlis NJ; Belch A; Krishnan A; Vescio RA; Mateos MV; Mazumder A; Orlowski RZ; Sutherland HJ; Bladé J; Scott EC; Oriol A; Berdeja J; Gharibo M; Stevens DA; LeBlanc R; Sebag M; Callander N; Jakubowiak A; White D; de la Rubia J; Richardson PG; Lisby S; Feng H; Uhlar CM; Khan I; Ahmadi T; Voorhees PM
    Lancet; 2016 Apr; 387(10027):1551-1560. PubMed ID: 26778538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of Daratumumab Following Intravenous Infusion in Relapsed or Refractory Multiple Myeloma After Prior Proteasome Inhibitor and Immunomodulatory Drug Treatment.
    Clemens PL; Yan X; Lokhorst HM; Lonial S; Losic N; Khan I; Jansson R; Ahmadi T; Lantz K; Zhou H; Puchalski T; Xu XS
    Clin Pharmacokinet; 2017 Aug; 56(8):915-924. PubMed ID: 27896689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy of Daratumumab Monotherapy and Pomalidomide Plus Low-Dose Dexamethasone in the Treatment of Multiple Myeloma: A Matching Adjusted Indirect Comparison.
    Van Sanden S; Ito T; Diels J; Vogel M; Belch A; Oriol A
    Oncologist; 2018 Mar; 23(3):279-287. PubMed ID: 29192016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study.
    Jullien M; Trudel S; Tessoulin B; Mahé B; Dubruille V; Blin N; Gastinne T; Bonnet A; Lok A; Lebourgeois A; Peterlin P; Garnier A; Chevalier P; Guillaume T; Thomaré P; Le Gouill S; Moreau P; Touzeau C
    Ann Hematol; 2019 Jun; 98(6):1435-1440. PubMed ID: 30874850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma.
    Lokhorst HM; Plesner T; Laubach JP; Nahi H; Gimsing P; Hansson M; Minnema MC; Lassen U; Krejcik J; Palumbo A; van de Donk NW; Ahmadi T; Khan I; Uhlar CM; Wang J; Sasser AK; Losic N; Lisby S; Basse L; Brun N; Richardson PG
    N Engl J Med; 2015 Sep; 373(13):1207-19. PubMed ID: 26308596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daratumumab monotherapy compared with historical control data in heavily pretreated and highly refractory patients with multiple myeloma: An adjusted treatment comparison.
    Usmani SZ; Diels J; Ito T; Mehra M; Khan I; Lam A
    Am J Hematol; 2017 Aug; 92(8):E146-E152. PubMed ID: 28474745
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.